Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3356MR)

This product GTTS-WQ3356MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Canine B-cell lymphoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Caninized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AT-004(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3356MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1839MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ1291MR IVTScrip™ mRNA-Anti-RGMA, ABT-555(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABT-555
GTTS-WQ14667MR IVTScrip™ mRNA-Anti-DPEP3, SC-003 mAb(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC-003 mAb
GTTS-WQ1859MR IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA AGEN1884
GTTS-WQ11204MR IVTScrip™ mRNA-Anti-TNFRSF18, MEDI-1873(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEDI-1873
GTTS-WQ14871MR IVTScrip™ mRNA-Anti-SLC39A6, SGN-LIV1A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-LIV1A
GTTS-WQ15266MR IVTScrip™ mRNA-Anti-phosphatidylserine, Tarvacin ch3G4(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA Tarvacin ch3G4
GTTS-WQ3889MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BCD-100
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW